Ovarian cancer is the fifth leading cause of cancer deaths among women¹
Approximately 21,290 women will be diagnosed with ovarian cancer in 2015¹
Approximately 14,180 women will die from ovarian cancer in 2015¹
Patients with a personal and/or family history of ovarian cancer may be at risk for hereditary cancer
Approximately 10-15% of ovarian cancers occur from inherited genetic mutations.² Clinical research has validated that there are several genes that are linked to hereditary ovarian cancer.
(n= 648 patients)
Data confirms the benefits of multigene panel testing among patients at risk for hereditary ovarian cancer
Data presented at ASCO in June 2014 by Lucy R. Langer, MD, from U.S. Oncology illustrated that in 648 patients with ovarian cancer, 34% of the pathogenic mutations identified with Myriad myRisk® were outside of BRCA1/2 and the genes associated with Lynch syndrome.⁴ This means that 42 patients with cancer-causing mutations would have been missed if they were simply tested for BRCA1/2 or Lynch syndrome mutations and there would not have been an opportunity to optimize patient care based on hereditary cancer status.
Myriad myRisk identifies ~40-50%³˒⁴ more mutations than syndrome-specific testing across 8 common cancer sites
“Advantages of cancer gene panels include decreased cost and improved efficiency of cancer genetic testing by decreasing the time involved, number of patient visits, and number of tests sent. A negative genetic test is more reassuring at eliminating the likelihood of inherited risk when all known genes for that phenotype have been assayed.” ⁷
SGO Clinical Practice Statement: Next Generation Cancer Gene Panels Versus Gene by Gene Testing, March 2014
Multigene panel testing provides accurate results and clear management recommendations for patients with increased cancer risks
Testing with the Myriad myRisk hereditary cancer panel:
- Provides confidence in knowing your patients’ risks and clear direction on the recommended management options to reduce their risks
- Rapid turnaround time of 14-21 days for test results
- The Myriad myRisk Management Tool provides a summary of national guidelines to help you optimize your patients’ care
- Myriad’s commitment to patients and their families is demonstrated with its industry-leading variant classification program, myVision®. Myriad’s myVision is the world’s most advanced approach to the classification and reclassification of variants of uncertain significance -using more validated classification methods and higher classification standards than any other laboratory.
Know the red flags associated with hereditary cancer:
Red Flags for Hereditary Cancer
An individual with a personal or family history of any ONE of the following:
A combination of cancers on the same side of the family
Any 1 of the following cancers at age 50 or younger
Any 1 of these rare presentations at any age
††Presence of tumor infiltrating lymphocytes, Crohn’s-like lymphocytic reaction, mucinous/signet-ring differentiation, or medullary growth pattern.
Assessment criteria based on medical society guidelines. For these individual medical society guidelines, go to www.MyriadPro.com/guidelines.
Family members include first-, second-, and third-degree blood relatives on both your mother and father’s sides.
Certain ancestries may have greater risk for hereditary cancer syndromes (e.g., Ashkenazi Jewish ancestry)
Be confident in knowing your patients’ cancer risks and specific medical management options with the Myriad myRisk Hereditary Cancer Panel
For more information about the data presented by Dr. Langer, please see the data summary.
- A Study of Ovarian Cancer Patients Tested With a 25-gene Panel of Hereditary Cancer Genes, Lucy R. Langer et. al. Presented at ASCO June 2014
- Prevalence of Gene Mutations Among Hereditary Breast and Ovarian Cancer Patients Using a 25-gene Panel, Nadine Tung et. al. Presented at ACMG in March 2014
- Multi-gene panel testing in patients suspected to have Lynch syndrome, Matthew B. Yurgelun et. al. Presented at ASCO June 2014
- SGO Clinical Practice Statement: Next Generation Cancer Gene Panels Versus Gene by Gene Testing, March 2014